期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 74, 期 -, 页码 302-313出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2013.12.045
关键词
Cancer chemotherapy; Tumor targeting; Glucuronide prodrugs; Self-immolative linkers
资金
- La Ligue Nationale contre le Cancer (Comities of Charente, Charentes-Maritime, Vienne and Deux Sevres)
- Agence Nationale de la Recherche (ARN, Programme Blanc - SIMI 7, ProTarget)
The design of novel antitumor agents allowing the destruction of malignant cells while sparing healthy tissues is one of the major challenges in medicinal chemistry. In this context, the use of non-toxic prodrugs programmed to be selectively activated by beta-glucuronidase present at high concentration in the microenvironment of most solid tumors has attracted considerable attention. This review summarizes the major progresses that have been realized in this field over the past ten years. This includes the new prodrugs that have been designed to target a wide variety of anticancer drugs, the prodrugs employed in the course of a combined therapy, the dendritic glucuronide prodrugs and the concept of beta-glucuronidase-responsive albumin binding prodrugs. (C) 2014 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据